First-in-human therapeutic interfering particle (tip) targeting a respiratory virus
Ended Definitive Contract Awarded Last action
- Contract number
- 140D0420C0006
- Awardee
-
Autonomous Therapeutics Inc. UEI JFHPX6TUYMU8
- Awarding agency
-
Interior Business Center
Office of Policy Management and Budget, Department of the Interior
- Obligated
- $3,247,731
Award facts
- Opportunity
-
- FY19BAA Solicitation number
- Contract value 100% obligated
- $3,247,731.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Funding agency
- Defense Advanced Research Projects Agency Department of Defense
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- North Bethesda, MD 20852, USA
- Research
- SBIR Program Phase II Action
- Legislative mandates
-
- Other statutory authority
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Close Out | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $999,974 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $1,076,198 | |
| Original award | $1,171,559 |
About this award
This is a $3,247,731 definitive contract awarded by the Defense Advanced Research Projects Agency (DARPA) to Autonomous Therapeutics Inc., a small business biotechnology company. The contract is for the development of a first-in-human therapeutic interfering particle targeting a respiratory virus, under DARPA's research programs. Autonomous Therapeutics has also been awarded an Indefinite Delivery Vehicle (IDV) by DARPA, with a potential value of $4,579,822, to develop and deliver therapeutic interfering particles against respiratory viral threats, including MERS-CoV. Additionally, the company has received a Small Business Innovation Research (SBIR) Phase II contract from the Naval Air Systems Command, valued at approximately $1 million, and a $273,644 grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance its antiviral research capabilities. These awards highlight Autonomous Therapeutics' expertise in developing innovative medical countermeasures against respiratory viral threats, leveraging synthetic biology and advanced drug delivery technologies.
Quick answers
Who was awarded contract 140D0420C0006?
140D0420C0006 was awarded to Autonomous Therapeutics Inc. by Interior Business Center (Office of Policy Management and Budget) on February 21, 2020.
How much is contract 140D0420C0006 worth?
The government has obligated $3,247,731 on 140D0420C0006.
Which agency awarded contract 140D0420C0006?
Interior Business Center (Office of Policy Management and Budget) awarded 140D0420C0006, with funding from Defense Advanced Research Projects Agency (Department of Defense).
Was contract 140D0420C0006 competed?
The extent of competition for 140D0420C0006 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award